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Abstract
Background/Aims—Retaining patients in prevention of mother-to-child transmission of HIV 
studies can be challenging in resource limited settings, where high lost to follow-up (LTFU) rates 
have been reported. In this paper, we describe the effectiveness of methods used to encourage 
retention in the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study and analyze factors 
associated with LTFU in the study.
Methods—The BAN clinical trial was designed to evaluate the efficacy of 3 different mother-to-
child HIV transmission prevention strategies. Lower than expected participant retention prompted 
enhanced efforts to reduce LTFU during the conduct of the trial. Following study completion, we 
employed regression modeling to determine predictors of perfect attendance and variables 
associated with being LTFU.
Results—During the study, intensive tracing efforts were initiated after the first 1686 mother-
infant pairs had been enrolled, and 327 pairs were missing. Sixty of these pairs were located and 
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had complete data obtained. Among the 683 participants enrolling after initiation of intensive 
tracing efforts, the LTFU rate was 3.4%. At study's end, 290 (12.2%) of the 2369 mother-infant 
pairs were LTFU. Among successfully traced missing pairs, relocation was common and three 
were deceased. Log-binomial regression modeling revealed higher maternal hemoglobin and older 
maternal age to be significant predictors of perfect attendance. These factors and the presence of 
food insecurity were also significantly associated with lower rates of LTFU.
Conclusions—In this large HIV prevention trial, intensive tracing efforts centered on reaching 
study participants at their homes succeeded in finding a substantial proportion of LTFU 
participants, and were very effective in preventing further LTFU during the remainder of the trial. 
The association between food insecurity and lower rates of LTFU is likely related to the study's 
provision of nutritional support, including a family maize supplement, which may have 
contributed to patient retention.
Keywords
Antiretroviral therapy; human immunodeficiency virus; lost to follow up; prevention of mother to 
child transmission; retention; tracing
Background/Aims
Retaining patients in prevention of mother-to-child HIV transmission studies or 
antiretroviral treatment programs is a major challenge in resource-limited settings. Recent 
large prevention of mother-to-child transmission trials have experienced percentages of lost 
to follow-up (LTFU) ranging from 3.5% at 7 months in a study conducted in Botswana1 to 
14.0% at 9 months in a trial conducted in Malawi.2 HIV treatment programs in similar 
settings have also reported substantial LTFU. For patients starting antiretroviral therapy 
between 2004 and 2007 at public sector clinics in Malawi, the reported LTFU percentage 
was 10.0% at 12 months.3 One large systematic review of retention in antiretroviral 
treatment programs in sub-Saharan Africa found a weighted average of 13.0% LTFU at 12 
months for the 33 antiretroviral therapy programs evaluated.4
Factors that potentially influence LTFU in prevention of mother-to-child transmission trials 
and treatment programs in developing countries include stigma and lack of disclosure to 
family, medication side effects, transportation costs, health of participants, gender of the 
infant, education level, occupation, study complexity, and lack of telecommunications 
infrastructure.5-10 In some settings, a significant proportion of program attrition is due to 
unrecognized patient deaths11, which could also be a significant contributor to LTFU in 
prevention of mother-to-child transmission trials.
The sample size for clinical trials is determined by predictions of the comparative efficacy 
of study interventions and LTFU during the study period. The Breastfeeding, 
Antiretrovirals, and Nutrition (BAN) clinical trial was designed with a sample size of 2418 
and an expected LTFU of 10% by 28 weeks.12 Higher LTFU would result in decreased 
statistical power to detect a significant difference between the study arms or require 
increased enrollment of participants with resultant increased cost and delay in determining 
the study outcome. In this paper, we describe the methods used to minimize LTFU in the 
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BAN study, the effectiveness of these methods for study retention, and factors associated 
with LTFU in our study.
Methods
Description of the BAN study
The BAN study has been described in detail previously.12-15 Briefly, investigators recruited 
pregnant women who tested HIV positive through a prevention of mother-to-child 
transmission program from four antenatal clinics, with outreach to all pregnant women in 
Lilongwe, Malawi, from April 2004 to January 2009. Primary eligibility criteria included 
age of at least 14 years, hemoglobin > 7 g/dl, alanine aminotransferase < 2.5 times the upper 
limit of normal, no history of antiretroviral drug use, and a CD4 T cell count of 250/μL or 
more (before July 24, 2006, a CD4 T cell count of ≥200/μL was used; this change was in 
accordance with the Malawi Ministry of Health guidelines for HIV treatment). After 
delivery, women and their infants were eligible for randomization if they met the secondary 
eligibility criteria: presentation at the study site within 36 hours of delivery, infant birth 
weight ≥2000 g, no severe congenital malformations or conditions incompatible with infant 
survival, and no maternal condition that would preclude start of the study interventions 
(based on clinical assessment). Ineligible women were referred to an HIV treatment facility. 
Infants found to be HIV-infected at birth or in the first 2 weeks of life were dis-enrolled 
from the BAN study and referred for care. All women provided written informed consent. 
The BAN study protocol was approved by the Malawi National Health Science Research 
Committee and by institutional review boards at the University of North Carolina at Chapel 
Hill and the United States Centers for Disease Control and Prevention. The study was 
approved and overseen by a Vaccine and Prevention Data Safety and Monitoring Board at 
the National Institutes of Health.
Mother-infant pairs were randomized within one week of delivery in a 2 × 3 factorial design 
to a two-arm maternal nutritional intervention (nutritional supplement and no supplement) 
and a three-arm antiretroviral intervention for up to 28 weeks (maternal antiretrovirals, 
infant nevirapine, and control group). Irrespective of antiretroviral treatment assignment, all 
mothers in labor and their newborn infants were given single-dose nevirapine and 
zidovudine and lamivudine for 7 days. Additionally, all women received 2 kg/week maize 
flour for 48 weeks. The interventions were initiated immediately following delivery and 
were continued until the cessation of breast-feeding but no longer than 28 weeks 
postpartum. All mothers enrolled in the study were counselled to exclusively breastfeed for 
24 weeks and then wean over a 4-week period.
Mother-infant pairs were followed at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 32, 36, 42, and 48 
weeks postpartum or until a study endpoint was reached. In this study three events were 
considered as endpoints: infant HIV infection, infant death and maternal death. Infants were 
tested in real-time for HIV infection at birth and at 2, 12, 28, and 48 weeks with the use of 
the Roche Amplicor 1.5 DNA polymerase chain reaction assay.
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Retention strategies
The BAN study developed several strategies to maximize participant retention prior to 
beginning enrollment. In designing the study, strategies to foster community involvement 
and cultural acceptability included interviews, focus groups and home visits. These have 
been described at length elsewhere.16 During the study, routine strategies included support 
groups, home visits, transportation to and from study visits, frequent attempts to contact 
clients to reschedule missed visits, provision of treatment for intermittent infections, and 
involving husbands or partners by encouraging them to accompany the study participants to 
the clinic. Partners were offered HIV counseling and testing and referral to other health 
services. Study participants also received the equivalent of $4 in Malawi Kwacha at each 
study visit and the equivalent of $10 for the delivery visit to reimburse for transportation 
costs.
At enrollment, all the women were asked for locator information which was recorded on a 
locator form. They were asked for permission to have study staff call or visit them at their 
home or work place if necessary during the study. Telephone contact numbers were 
collected, though some participants did not have a telephone. Since there are no street 
addresses for most locations in Malawi, directions to participants' homes or work places 
were often mapped, with important landmarks, on the locator forms. Study staff asked 
permission to contact a spouse and another person; if granted, this contact information was 
recorded on the locator form. At each subsequent visit, the locator information was verified 
and updated if necessary by a reception nurse.
The BAN study community nurses conducted weekly support group meetings. All study 
participants were encouraged to attend these support group meetings as often as possible. 
Home visits were made to all women at least once to help provide support during 
breastfeeding. This gave an opportunity to verify the locator information. Extra home visits 
were made to women in need of additional counseling or support.
Tracing missing study participants
The BAN study included a team of six community nurses and drivers whose work focused 
on retention through tracing the study participants in the community by phone or vehicle. 
Tracing attempts were made by the community study staff within 48 hours for all women 
who missed a scheduled follow-up visit. Staff would determine the reason for the missed 
visit and try to resolve the issue so that the woman could come for her visit.
Study participants who were not found or did not report for more than two weeks after an 
initial tracing visit were considered missing. At a minimum, a second attempt to locate the 
mother-infant pair was made. If the pair was unable to be located, a termination form was 
completed to document the dates and outcome of tracing attempts, as well as any additional 
information about the pair's possible whereabouts or reasons for not reporting.
Efforts to locate missing study participants
Despite routine immediate tracing for missed visits, interim data analysis in November, 
2007 after 1686 pairs had been enrolled revealed a higher-than-expected proportion of pairs 
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without a study endpoint or a week-28 study visit. In 2008, we intensified our efforts to find 
pairs that had not been located by standard tracing efforts. Weekly staff meetings and 
additional strategy sessions were employed to increase focus on improving retention. We 
searched the study database for infants due to have reached their 28 week study visit but 
with missing HIV DNA results. For these cases, extensive tracing efforts focused on 
determining their vital and HIV status.
The BAN Study developed several innovative efforts to find lost participants. In 2008, the 
study broadcast a radio announcement in Chichewa, the local language, on two radio 
stations three times per day for six days over a two-week period. It identified the study 
without mentioning HIV and asked participants to return to the clinic if they had not 
completed the study. In June 2008, we hired a community educator to trace missing 
participants via motorcycle. A motorcycle was chosen due to input from the tracing staff that 
some villages were difficult to reach by larger vehicle due to poor roads, particularly during 
the rainy season. Logos that would identify it as belonging to an HIV study were avoided in 
order to minimize possible stigma. Upon arrival at a home the community educator noted if 
the pair was found, and if the mother and infant were alive. If either of them had died, the 
tracer attempted to ascertain the cause and date of death. If the pair were found alive, the 
community educator would request that they come to the study clinic for HIV DNA testing 
on the child. Additionally, we collected a specimen for maternal CD4 count to determine 
antiretroviral eligibility and promote referral to an antiretroviral clinic for continued care. 
Pairs that were found but still did not come back to the clinic were visited again and offered 
home collection of blood for infant HIV DNA testing and maternal CD4 count. The 
intensive tracing and retention policies initiated in 2008 were continued for the remainder of 
the study, so that all pairs who missed visits after that time were intensively traced and, if 
they refused further participation in the study, were offered in-home blood collection for 
infant HIV DNA testing. From this tracing, we learned that some missing participants had 
relocated to areas outside of Lilongwe. Therefore, we expanded our tracing radius to include 
all districts in Malawi. When a specific location for the participant's residence could be 
obtained, community educators organized trips throughout the country to trace missing 
study participants.
Statistical analysis methods
To examine predictors of missed visits, we defined the outcome as missing at least one 
scheduled study visit between zero and 28 weeks post-partum, choosing 28 weeks because 
this represented the time point for the primary outcomes of the BAN study. Pairs where an 
infant HIV infection, infant death, or maternal death endpoint was observed by 28 weeks 
were considered to have perfect attendance if no scheduled visits were missed prior to the 
endpoint. Pairs where the infant was not infected and neither the mother nor infant died by 
28 weeks were considered to have perfect attendance if they attended all 11 scheduled study 
visits between 0 (birth) and 28 weeks. Log-binomial regression models were fit to assess 
associations between participant covariates and risk of missing at least one scheduled visit. 
As a sensitivity analysis, log-binomial regression models were also fit modeling the 
probability of missing at least two visits.
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Cox regression models were employed to determine variables associated with the hazard of 
being LTFU. The Cox model has the advantage over the log-binomial model of being able 
to incorporate time-varying covariates, such as the occurrence of an adverse event. A 
mother-infant pair was defined as LTFU if their last study visit was prior to 28 weeks and at 
that visit the mother and infant were alive and the infant was HIV negative. For the Cox 
model, mother-infant pairs where the infant became HIV infected (prior to 28 weeks) were 
right censored at their first positive visit; mother-infant pairs where the mother or HIV-
negative infant died (prior to 28 weeks) were right censored at the time of death. Mother-
infant pairs not categorized as LTFU prior to week 28 were right censored at 29 weeks.
Covariates for possible inclusion in the log-binomial and Cox regression models were 
initially considered if believed a priori to be potentially associated with missed visits based 
on the existing literature or BAN study operational experience. Covariates marginally 
associated with the outcome at the 0.10 significance level were retained in the multivariate 
regression models. Collinearity between covariates was assessed using Pearson's correlation 
coefficient. As a sensitivity analysis, models were fit dropping each potentially collinear 
covariate, and results that differed from the final adjusted model were reported.
Results
Recruitment
The BAN study started enrolling participants in April 2004 and completed follow-up on the 
last participant in February 2010. By the end of the study, a total of 3572 women consented 
to study screening, 3109 met primary eligibility criteria, and 2791 delivered live-born 
infants. A total of 2382 mother-infant pairs met secondary eligibility criteria following 
delivery, and 2369 agreed to enroll in the study and were randomized.
Yield of intensive tracing efforts
Prior to implementation of enhanced intensive tracing efforts in November 2007, there were 
327 mother-infant pairs classified as missing, based on the absence of a 28-week infant HIV 
DNA result in those for whom study endpoints of death or infant HIV infection had not 
occurred, out of 1686 enrolled (19.4%). Of these 327 mother-infant pairs, 102 (31.2%) were 
found. For 60 mother-infant pairs (18.3% of the 327 missing), study endpoint data were 
obtained, consisting of 57 infants for whom HIV DNA tests were performed and 3 infants 
who were confirmed to have died. The remaining 42 pairs were comprised of infants that 
were alive but whose mothers either withdrew from the study by refusing further 
participation (n=18) or failed to bring the infant for final HIV DNA testing (n=24) (Figure 
1). There were 225 pairs that were not located. Of these, 13 had no locator information and 
121 were reported to have relocated. There were several reports of women having moved to 
other parts of the country for employment, to help with the harvest, or to return to their 
home village after the death of a husband. Additionally, eight infants and two mothers were 
reported to have died after 28 weeks.
At the conclusion of intensive tracing efforts, the 225 pairs that were not located and the 42 
who were found but for whom study endpoint data could not be collected were classified as 
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LTFU, a total of 267 pairs (15.8%). Over the remaining study period after the initiation of 
intensive tracing efforts in November 2007, an additional 23 out of 683 (3.4%) became 
LTFU, resulting in 290 LTFU LTFU pairs out of 2369 pairs who received treatment 
assignment (12.2%) (Figure 1).
Study attendance
Mother-infant pairs that were LTFU did not differ significantly from those not LTFU by the 
antiretroviral or nutritional arm to which they had been randomized (Table 1). Also, the 
mothers who were LTFU did not differ significantly from those not LTFU on some baseline 
demographic and laboratory characteristics, including whether living with partner, whether 
widowed, and baseline CD4 count. However, there were statistically significant differences 
in maternal age (p<0.001) and maternal body mass index at delivery (p=0.03), and whether 
this was the mother's first pregnancy (p<0.001). Of the 2369 mother-infant pairs 
randomized, 1688 (71%) had perfect attendance and an additional 218 (9.2%) missed only 
one visit prior to completing the study at 28 weeks postpartum or reaching a study endpoint. 
Among the 184 infants HIV-positive by week 28, 92% had perfect attendance prior to their 
HIV test. Among the 29 infants who died, 93% had perfect attendance prior to death.
Predictors of missed visits
In the adjusted log-binomial regression model, maternal hemoglobin and maternal age were 
significantly associated with missing one or more visits (Table 2). For each one unit increase 
in maternal hemoglobin (g/dL), the risk of missing one or more visits was reduced by 6% 
(RR=0.94, 95% CI 0.89, 0.98, p=0.009). Additionally, there was a 5% decrease in the risk of 
missing more than one visit for each year increase in maternal age (RR=0.95, 95% CI 0.94, 
0.96, p<0.001). There was a significant negative association (i.e., collinearity) between 
maternal age and first pregnancy (p<0.001). When either age or first pregnancy was 
excluded from the adjusted model, results were nearly identical except that when maternal 
age was excluded, the RR estimate for first pregnancy was 1.54 (95% 1.32, 1.80; p<0.001). 
Log-binomial regression models of predictors of two or more missed visits yielded similar 
results (data not shown).
Predictors of being LTFU
In unadjusted Cox regression models of the rate of LTFU, factors significantly associated 
with increased hazard of LTFU were lower infant weight-for-age, lower maternal 
hemoglobin, younger maternal age, lower maternal body mass index at delivery, food 
security, and this not being a mother's first pregnancy (Table 3). In the adjusted Cox model, 
infant weight-for-age, maternal body mass index at delivery, and first pregnancy were no 
longer significantly associated with LTFU. Maternal hemoglobin was significantly 
associated with LTFU in the adjusted model, with a 17% (95% CI 6%, 26%) lower rate of 
LTFU per one unit increase in hemoglobin (grams/deciliter) (p=0.002). Maternal age was 
significantly associated with a 6% (95% CI 3%, 10%) lower rate of LTFU per one year 
increase in age. Additionally, the presence of food insecurity, defined as any self-reported 
food shortage within the past 4 weeks, was significantly associated with a 42% (95% CI 
10%, 63%) lower rate of LTFU (Table 3). Sensitivity analyses excluding potentially 
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collinear covariates yielded nearly identical results, except that when maternal age was 
excluded the hazard ratio estimate for first pregnancy was 1.67 (95% CI 1.14, 2.44; p=0.01).
Discussion
Intensive tracing efforts in the BAN study reduced the percent missing from 19.4% to 
12.2%. Despite the decrease, this was still higher than the expected LTFU of 10% used 
when designing the study and determining the target sample size. Of the 327 mother-infant 
pairs missing at the start of intensive tracing, primary study endpoint data were able to be 
collected on a total of 60, representing 58.8% of those who were found and 18.3% of the 
total missing. The intensive tracing strategies were continued for the remainder of the study 
and their impact was reflected in a LTFU rate of only 3.4% in the 683 mother-infant pairs 
who began the study after November 2007. This striking improvement reveals the improved 
effectiveness of intensive tracing when conducted in real time as opposed to retroactively, 
by which time missing study participants could have relocated. The emphasis on retention to 
study staff may also have resulted in better location information and better patient 
counseling regarding study attendance.
In addition to reducing LTFU, tracing efforts yielded information about reasons for study 
attrition. Of the 327 missing pairs at the start of intensive tracing, 225 (69%) were unable to 
be located, highlighting the need for better tracing methods. The 121 of these reported to 
have relocated likely represent an underestimate of population mobility, since some of those 
for which no information was found may also have relocated. Previous studies in sub-
Saharan Africa have implicated both mobile populations17 and transportation costs18 in loss 
to follow-up. In addition to the reasons suggested above, the frequent lack of street 
addresses in Lilongwe likely contributed. Use of global positioning system technology to 
more precisely identify the location of participants' homes has been reported with success in 
HIV prevention trials19 and has subsequently been used for a malaria vaccine study in 
Lilongwe, Malawi.20 Our data and analysis are insufficient to determine whether there 
would have been a benefit in the BAN study.
Unrecognized infant and maternal mortality may have contributed to LTFU in our study. 
Among successfully traced participants, we discovered three infant deaths at prior to 28 
weeks and ten mother or infant deaths after 28 weeks, but there may have been additional 
deaths among LTFU participants who were not found. In other studies in Africa, 30-46% of 
successfully traced participants were found to have died.10,21,22 The high mortality seen in 
these cases highlights the urgency of retaining and tracing participants in studies both for 
accurate evaluation of study outcomes and to ensure appropriate and possibly life-saving 
medical care is provided.
Some of our participants did not provide a phone number. Telephone ownership has 
increased dramatically across Africa in recent years with the increasing affordability of 
mobile phones.23 Cell phone costs in Malawi fell from approximately $100 in 2004 to $20 
in 2008. Providing cell phones for mothers might have been a cost-effective intervention 
compared to the amount spent on transportation costs and salaries for our community 
educators. The presence of a contact phone number was found in an antiretroviral study to 
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double the success rate of tracing lost patients10 and found to be an acceptable and useful 
tool in the health sector in Africa.23,24
Our analyses of patient-specific factors associated with LTFU revealed several interesting 
associations. Regression modeling revealed younger mothers were more likely to become 
LTFU. This may reflect older women being at a more stable point in their lives in terms of 
day-to-day activities, ability to keep their appointments, or likelihood of remaining in one 
area.
Interestingly, lower baseline maternal hemoglobin was associated with missed visits and 
LTFU while other health and nutrition-related covariates such as maternal CD4, maternal 
body mass index and maternal adverse events were not. We postulate that the association 
with hemoglobin is due to aspects of health not captured in these other variables. Maternal 
body mass index was measured immediately after delivery and likely has a much less 
predictable relationship to health and nutrition than body mass index in non-pregnant 
individuals. Exclusion of mothers with low (<250) CD4 counts from the BAN study could 
have obscured an association of maternal CD4 with retention. Anemia could result in missed 
visits due to poor health that would not qualify as specific adverse events, such as via 
decreased energy making the trip to clinic more onerous. It could also predispose to more 
severe illnesses which could prompt unannounced relocation and consequent study dropout, 
or even lead to undiscovered deaths.
A history of food insecurity was associated with being retained in the study. Women 
experiencing food insecurity may have been more motivated to attend visits by the study's 
provision of a maternal nutritional supplement to half of the women, a family maize 
supplement to all participants at each visit, and a weaning supplement for all the infants. In 
some instances, food insecurity has been shown to be associated with non-adherence to 
antiretroviral therapy.25,26 However, studies have also suggested an association between the 
provision of food supplementation and retention in HIV programs.27,28 Our results are 
consistent with the idea that nutritional support can be a positive factor for adherence in 
settings with food shortages.
In the BAN Study, 71% of mother-infant pairs achieved perfect attendance, an impressively 
high percentage in light of the 11 required visits for post-partum mothers and newborn 
infants, as well as the limited resources and widespread poverty of the study setting. 
However, the 12.2% LTFU at 28 weeks in our study was higher than anticipated, but in 
keeping with that seen in other large prevention of mother-to-child transmission studies in 
sub-Saharan Africa. Our study's intensive community-based efforts and statistical analysis 
of predictors of LTFU may offer some insight into ways to minimize losses to follow-up in 
future studies. The dramatic reduction of LTFU rate to 3.4% for pairs enrolled after the 
implementation of intensive tracing efforts also suggests a large benefit to a proactive rather 
than reactive approach to retention. The BAN study experience highlights the benefits of 
determined, community-based tracing efforts and also the difficulties presented by lack of 
fixed contact information and minimal telephone contacts. This suggests a role for increased 
use of mobile phones to improve study retention and enhance patient care. Large clinical 
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trials, such as the BAN study, may prove to be useful test cases for the feasibility of 
innovative strategies such as this.
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Figure 1. 
Enrollment and outcomes in the BAN Study, including results of intensive tracing efforts in 
2007 and 2008 on 327 missing mother-infant pairs.
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Table 1
Baseline characteristics of the mothers in the BAN trial by LTFU status at end of studya.
LTFU (n=290) Not LTFU (n=2079) p-valueb
Maternal age, median (interquartile range) 24 (21,27) 26 (23, 30) <.001
Living with partner 266 (91.7%) 1936 (93.1%) 0.32
Widowed 0 (0.0%) 24 (1.2%) 0.96
Ever married 281 (96.9%) 2037 (98.0%) 0.21
Walks to clinic 4 (2.6%) 44 (4.7%) 0.31
ARVc arm
 Mother ARV 103 (35.5%) 749 (36.0%) 0.58
 Infant NVP 103 (35.5%) 746 (35.9%)
 No ARV 84 (29.0%) 584 (28.1%)
Maternal CD4 count >350 at baseline 200 (69.0%) 1462 (70.3%) 0.38
Median CD4 (interquartile range) 448 (318, 612) 437 (330, 573) 0.44
First pregnancy 60 (21.3%) 224 (11.2%) <.001
Maternal body mass index at delivery (median) 22.8 23.2 0.03
Infant adverse event at birth 3 (1.0%) 21 (1.0%) 0.81
Maternal adverse event at delivery 2 (0.7%) 10 (0.5%) 0.54
aNumber of subjects with missing data by variable: age (n=7), walks to clinic (n=1276), first pregnancy (n=83), and maternal body mass index at 
delivery (n=243).
b
Based on Cox proportional hazards models with each characteristic as the sole covariate in the model
cAntiretroviral
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Table 2
Log-binomial regression modeling of significant predictors for one or more missed visits versus no missed 
visits by 28 weeks adjusted for all variables in the table. a, b
Predictorsa Missed one or more visits Risk Ratio (95% CI) P-value
Maternal hemoglobin at baseline (per increase of 1 
g/dl)
Observed (2274) 660 (29.0%) 0.94 (0.89, 0.98) 0.009
Maternal age at baseline (per increase of 1 year) Observed (2274) 660 (29.0%) 0.95 (0.94, 0.96) <.001
First pregnancy No (1990, 87.5 %) 541 (27.2%) 1.0 (referent) 0.16
Yes (284, 12.5%) 119 (41.9%) 1.13 (0.95, 1.35)
a
This table only includes covariates that were significant at the 0.10 level when included as the sole covariate in the model. The following 
covariates were not significant at the 0.10 level in univariate (i.e., unadjusted) models: living with partner, widowed, literate, education above 
primary school, ever married, walks to clinic, infant birth weight, infant adverse event at birth, maternal adverse event at delivery, maternal CD4 
count at baseline ≥350 cells/ul, and treatment arm.
bN = 2274 mother-infant pairs were included. 95 observations were excluded due to missing values of maternal hemoglobin (n=5), maternal age 
(n=7), or first pregnancy (n=83).
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Table 3
Cox regression modeling of possible risk factors associated with rate of lost to follow-up 
from 0 to 28 weeksa
Risk factor Unadjustedb Adjustedc
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Infant weight for age Z-score (per increase of 1 unit)d 0.87 (0.76, 1.00) 0.05e 0.95 (0.80, 1.11) 0.50
Maternal hemoglobin at baseline (per increase of 1 g/dl) 0.86 (0.78, 0.94) 0.002 0.83 (0.74, 0.94) 0.002
Maternal age at baseline (per increase of 1 year) 0.92 (0.89, 0.94) <.001 0.94 (0.90, 0.97) <.001
Maternal body mass index at delivery (per increase of 1 unit) 0.95 (0.90, 0.99) 0.03 0.96 (0.91, 1.02) 0.17
First pregnancy
 Yes 2.03 (1.51, 2.72) <.001 1.15 (0.75, 1.76) 0.52
 No 1.0 (referent) 1.0 (referent)
Any food insecurity (yes vs no) d, f
 Yes 0.67 (0.48, 0.93) 0.02 0.58 (0.37, 0.90) 0.02
 No 1.0 (referent) 1.0 (referent)
a
This table only includes covariates that were significant at the 0.10 level in unadjusted Cox models. The following covariates were not significant 
at the 0.10 level: living with partner, widowed, literate, education above primary school, ever married, walks to clinic, infant birth weight, infant 
adverse event at birth, infant adverse event between birth and 28 weeks, maternal adverse event at delivery, maternal CD4 count at baseline ≥350 
cells/ul, infant hemoglobin at delivery, and treatment arm.
bCox model with each risk factor as the sole covariate.
cCox model adjusted for all covariates in the table. N = 2033 mother infant pairs contributed to the adjusted model. 331 mother-infant pairs were 
excluded due to missing covariate values (n=243 missing maternal body mass index, n=83 missing first pregnancy, n=7 missing maternal age, n=5 
missing maternal hemoglobin, and n=1 missing weight for age z-score, with some pairs missing more than one covariate) and 5 additional infants 
were HIV positive (right censored) at birth
d
Time-dependent covariates, with last value carried forward when missing
e
P-value=0.046
fAny food shortage (self-report) in the last four weeks
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